Raltegravir (RAL)

DRUG3 trials

Sponsors

Abbott, International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionHIV InfectionsHuman Immunodeficiency Virus Infection

Phase 1

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

RecruitingNCT02140255

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2015-01-23End: 2031-12-31Target: 1120Updated: 2026-04-03

Phase 3

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

CompletedNCT00711009

AbbottHuman Immunodeficiency Virus Infection

Start: 2008-07-31End: 2010-10-31Updated: 2012-02-14

Unknown Phase

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

CompletedNCT00977756

International Maternal Pediatric Adolescent AIDS Clinical Trials GroupHIV Infections

Start: 2002-08-31End: 2014-03-31Updated: 2015-08-07

Related Papers

ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study.

2025-09-25

HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study.

2023-12-0410 citations

Infants Receiving Very Early Antiretroviral Therapy Have High CD4 Counts in the First Year of Life

Clinical Infectious Diseases2022-08-295 citations

Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.

2020-11-2312 citations

The Mission is Remission

The Pediatric Infectious Disease Journal2018-10-222 citations